Free Trial
→ SpaceX eyes a 1.75 trillion valuation - here's what to know (From Brownstone Research) (Ad)tc pixel
NASDAQ:CRBU

Caribou Biosciences Q3 2025 Earnings Report

Caribou Biosciences logo
$1.95 +0.02 (+1.04%)
Closing price 05/6/2026 04:00 PM Eastern
Extended Trading
$1.94 -0.01 (-0.56%)
As of 05/6/2026 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Caribou Biosciences EPS Results

Actual EPS
-$0.30
Consensus EPS
-$0.36
Beat/Miss
Beat by +$0.06
One Year Ago EPS
N/A

Caribou Biosciences Revenue Results

Actual Revenue
$2.20 million
Expected Revenue
$1.94 million
Beat/Miss
Beat by +$260.00 thousand
YoY Revenue Growth
N/A

Caribou Biosciences Announcement Details

Quarter
Q3 2025
Date
11/12/2025
Time
Before Market Opens
Conference Call Date
Wednesday, November 12, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

Caribou Biosciences' Q1 2026 earnings is estimated for Thursday, May 14, 2026, based on past reporting schedules, with a conference call scheduled on Friday, May 15, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Caribou Biosciences' Q3 2025 Earnings ReleaseEarnings Release
(8-K)

Caribou Biosciences Earnings Headlines

Caribou Biosciences to Participate in the BofA Securities 2026 Health Care Conference
May 5 at 4:05 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/05/3288251/0/en/caribou-biosciences-to-participate-in-the-bofa-securities-2026-health-care-conference.html
Caribou Biosciences (CRBU) price target decreased by 22.79% to 8.92
April 28, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/caribou-biosciences-crbu-price-target-decreased-by-22-79-to-8-92/ar-AA21WJ4a
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a $1.75 trillion IPO - larger than Saudi Aramco and any tech offering in history. CNBC calls it 'the big market event of 2026.' According to former tech executive and angel investor Jeff Brown, there's a way to claim a stake before the public filing drops, starting with as little as $500.tc pixel
 |  Brownstone Research (Ad)
Caribou rises on FDA RMAT designation for CAR-T therapy
April 1, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4570660-caribou-rises-fda-rmat-designation
Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy
March 31, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/31/3265437/0/en/caribou-biosciences-announces-the-fda-granted-regenerative-medicine-advanced-therapy-rmat-designation-to-cb-011-an-allogeneic-anti-bcma-car-t-cell-therapy.html
Leerink Partners Remains a Buy on Caribou Biosciences (CRBU)
March 11, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/CRBU/pressreleases/623687/leerink-partners-remains-a-buy-on-caribou-biosciences-crbu/
See More Caribou Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Caribou Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Caribou Biosciences and other key companies, straight to your email.

About Caribou Biosciences

Caribou Biosciences (NASDAQ:CRBU) is a clinical-stage biopharmaceutical company that leverages its proprietary CRISPR-Cas gene-editing platform to develop transformative cell therapies and in vivo treatments for a range of cancers and genetic diseases. The company’s core technology enables precise modification of cellular genomes, allowing the design of engineered T-cell and NK-cell therapies aimed at improving safety, efficacy and persistence in patients with hematologic and solid tumor malignancies. Alongside its oncology portfolio, Caribou is advancing in vivo editing programs targeting monogenic disorders, with initiatives in areas such as Duchenne muscular dystrophy and familial amyloidosis.

Established in 2011 and headquartered in Berkeley, California, Caribou Biosciences was co-founded by Nobel laureate Jennifer Doudna, one of the pioneers of CRISPR gene-editing technology. The company holds licenses to foundational CRISPR intellectual property from the University of California, enabling continuous innovation in genome engineering. Since completing its initial public offering in August 2021, Caribou has focused on progressing its clinical pipeline and expanding manufacturing capabilities to support its growing roster of investigational therapies.

Caribou’s leadership team combines deep expertise in molecular biology, clinical development and manufacturing scale-up, supported by an advisory board that includes leading figures in biotechnology and medicine. The company has established strategic collaborations with pharmaceutical and academic partners to advance its research programs and accelerate clinical translation. Caribou continues to conduct trials across multiple regions, aiming to bring its next-generation cell therapies and in vivo gene-editing treatments to patients worldwide.

View Caribou Biosciences Profile
Earnings Tools